Skip to main content

Advertisement

SpringerLink
Log in

Current Concepts of Neurocytoprotective Therapy

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

This review addressed the pharmacological effects and clinical efficacies of one of the “oldest” neurocytoprotective agents – Cerebrolysin. Experimental data identifying the molecular mechanisms of action of this agent are described in detail, along with results from clinical trials demonstrating the efficacy of Cerebrolysin in the treatment of acute and chronic cerebral ischemia, Alzheimer’s disease, and moderate and mild cognitive disorders. It is concluded that Cerebrolysin is an effective agent as demonstrated from the point of view of basic research (including in animal models and cell cultures) and numerous clinical trials in a variety of pathological states.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. V. V. Afanasiev, S. A. Rumyantseva, I. Yu. Lukyanova, et al., Proc. Emergency Care 2009 Conf. [in Russian], St. Petersburg (2009).

  2. S. A. Rumyantseva, V. V. Afanasiev, and E. V. Silina, “Pathophysiological bases of complex neuroprotection,” Zh. Nevrol. Psikhiat., 109, No. 3, 64–68 (2009).

    Google Scholar 

  3. S. A. Rumyantseva, V. A. Stupin, V. V. Afanasiev, et al., Critical States in Clinical Practice [in Russian], MIG, Meditsinskaya Kniga, Moscow (2011).

    Google Scholar 

  4. V. I. Skvortsova and L. V. Stakhovskaya, “Epidemiology of stroke in the Russian Federation,” in: Proc. Sci.-Appl. Conf. Acute Cerebrovascular Lesions [in Russian], Irkutsk (2011), pp. 7–14.

  5. H. Sommer and J. Quandt, “Zur Wirkung eines Hirnhydrolysates auf zentralnervoese Strukturen under Berucksichtigung elektronoptischer Ergebnisse,” Schweiz. Arch. Neurochir. Psychiat., 112, 373–386 (1973).

    CAS  Google Scholar 

  6. G. Lindner, G. Grosse, H. Matthies, and W. Kirsche, “Effects of brain extract and hydrolysate on nerve tissue in vitro,” Z. Mikrosk. Anat. Forsch., 89, No. 5, 815–823 (1975).

    PubMed  CAS  Google Scholar 

  7. S. V. Ukraintseva, K. B. Arbeev, A. I. Michalsky, and A. I. Yashin, “Antiaging treatments have been legally prescribed for approximately thirty years,” Ann. N.Y. Acad. Sci., 1019, 64–69 (2004).

    Article  PubMed  CAS  Google Scholar 

  8. O. A. Gromova,V. E. Tretiakov, S. A. Moshkovskii, et al., “An oligopeptide membrane fraction, Cerebrolysin,” Zh. Nevrol. Psikhiat., 106, No. 7, 68–70 (2006).

    CAS  Google Scholar 

  9. O. A. Gomazkov, Brain Aging and Neurotrophic Therapy [in Russian], Ikar Press, Moscow (2011).

    Google Scholar 

  10. T. H. Crook, S. H. Ferris, X. A. Alvarez, et al., “Effects of N-PEP-12 on memory among older adults,” Int. Clin. Psychopharmacol., 20, No. 2, 97–100 (2005).

    Article  PubMed  Google Scholar 

  11. H. Chen, Y. C. Tung, B. Li, et al., “Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis,” Neurobiol. Aging, 28, 1148–1162 (2007).

    Article  PubMed  CAS  Google Scholar 

  12. C. Zhang, M. Chopp,Y. Cu, et al., “Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke,” J. Neurosci. Res., 88, No. 15, 3275–3328 (2010).

    Article  PubMed  CAS  Google Scholar 

  13. Y. Tatebayashi, M. Lee, L. Li, et al., “The dentate gyrus neurogenesis: a therapeutic target for Alzheimer’s disease,” Acta Neurophysiol., 105, 225–232 (2003).

    CAS  Google Scholar 

  14. T. Satou, T. Itoh, H. Ohde, et al., “Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks,” J. Neural Transm., 107, No. 11, 1253–1262 (2000).

    Article  PubMed  CAS  Google Scholar 

  15. I. V. Damulin, N. N. Koberskaya, and E. A. Mkhitaryan, “Effects of Cerebrolysin on moderate cognitive impairment in cerebral ischemia (clinical-electrophysiological studies),” Zh. Nevrol. Psikhiat., 107, No. 5, 32–38 (2007).

    CAS  Google Scholar 

  16. D. F. Muresanu, X. A. Alvarez, H. Moessler, et al., “A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration,” J. Neurol. Sci., 267, No. 1–2, 112–119 (2008).

    Article  PubMed  CAS  Google Scholar 

  17. N. V. Vereshchagin, Z. A. Suslina, S. L. Timerbaeva, et al., “Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized, double-blind, placebo-controlled trial of Cerebrolysin,” Ter. Arkh., 73, No. 4, 22–27 (2001).

    PubMed  CAS  Google Scholar 

  18. S. Xiao, H. Yan, P. Yao, and the Cerebrolysin Study Group, “Efficacy of FPF 1070 (Cerebrolysin) in patients with Alzheimer’s disease,” Clin. Drug Invest., 19, 43–53 (2000).

  19. M. Tapu, D. Bicu, F. Tapu, and O. Stovicek, “The efficacy of Cerebrolysin in in vascular dementia,” J. Neurol. Sci., 283, No. 1–2, 286 (2009).

    Article  Google Scholar 

  20. A. B. Gekht, H. Moessler, P. H. Novak, and E. I. Gusev on behalf of the Cerebrolysin Investigators, “Cerebrolysin in vascular dementia: Improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial,” J. Stroke Cerebrovasc. Dis., 20, No. 3, 310–318 (2010).

    Google Scholar 

  21. E. I. Chukanova, “Effects of Cerebrolysin on the clinical signs and course of cerebral ischemia,” Zh. Nevrol. Psikhiat., No. 1, 42–45 (2005).

  22. V. R. Lombardi, M. Windisch, M. Garcia, and R. Cacabelos, “Effects of Cerebrolysin on in vitro primary microglial and astrocyte cell cultures,” Meth. Find. Exp. Clin. Pharmacol., 21, No. 5, 331–338 (1999).

    Article  CAS  Google Scholar 

  23. X. A. Alvarez, V. R. Lombardi, L. Fernandez-Novoa, et al., “Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection,” J. Neural Transm., 59, Supplement, 281–292 (2000).

    CAS  Google Scholar 

  24. M. Hartbauer, B. Hutter-Paier, G. Skofitsch, and M. Windisch, “Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons,” J. Neural Transm., 108, No. 4, 459–473 (2001).

    Article  PubMed  CAS  Google Scholar 

  25. B. Gutman, B. Hutter-Paier, G. Skofitsch, et al., “In vitro models of brain ischemia: the peptidergic drug Cerebrolysin protects chick cortical neurons from cell death,” Neurotoxicity Res., 4, No. 1, 59–65 (2002).

    Article  Google Scholar 

  26. E. Schauer, R. Wronski, J. Patockova, et al., “Neuroprotection of Cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window,” J. Neural Transm., 113, No. 7, 855–868 (2006).

    Article  PubMed  CAS  Google Scholar 

  27. E. Doppler, A. Alvarez, R. Cacabelos, et al., “Synergistic treatment effects with Cerebrolysin and donepezil: Results from a randomized, double-blind, multicenter trial to compare safety and efficacy of Cerebrolysin, donepezil and a combination treatment in patients with probable Alzheimer’s disease,” Alzheimer’s and Dementia, 5, No. 4, Suppl. 1, 248–249 (2009).

    Article  Google Scholar 

  28. H. Suchanek-Fröhlich and E. Wunderlich, “Randomisierte doppelblind- Placebo-Vergleichstudie mit einem Amino-Säure-Peptid- Extrakt,” Der Praktische Arzt, 41, No. 11, 1027–1034 (1987).

    Google Scholar 

  29. E. Ruether, R. Husmann, E. Kinzler, et al., “A 28-week, doubleblind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease,” Int. Clin. Psychopharmacol., 16, No. 5, 253–263 (2001).

    Article  PubMed  CAS  Google Scholar 

  30. E. Ruether, R. Ritter, M. Apecechea, et al., “Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy,” J. Neural Transm., 107, No. 7, Supplement, 815–829 (2000).

    Article  Google Scholar 

  31. C. Y. Bae, C. Y. Cho, K. Cho, et al., “A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease,” J. Am. Geriat. Soc., 48, No. 12, 1566–1571 (2000).

    PubMed  CAS  Google Scholar 

  32. D. F. Muresanu, M. Rainer, H. Moessler, “Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin,” J. Neural Transm., 62, Supplement, 277–285 (2002).

    CAS  Google Scholar 

  33. X. A. Alvarez, R. Cacabelos, M. Laredo, et al., “A 24-week, doubleblind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease,” Eur. J. Neurosci., 13, No. 1, 43–54 (2006).

    Article  CAS  Google Scholar 

  34. Z. H. Wei, Q. B. He, H. Wang, et al., “Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease,” J. Neural Transm., 114, No. 5, 629–634 (2007).

    Article  PubMed  CAS  Google Scholar 

  35. S. I. Gavrilova, Ya. B. Fedorova, I. V. Kolykhalov, et al., “Therapeutic potential of Cerebrolysin in the preventative treatment of Alzheimer’s disease,” Zh. Nevrol. Psikhiat., 108, No. 8, 24–28 (2008).

    CAS  Google Scholar 

  36. X. A. Alvarez, C. Sampedro, R. Cacabelos, et al., “Induced TNFalpha and increased IGF-1 levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent Cerebrolysin,” Int. J. Neuropsychopharmacol., 17, 1–6 (2009).

    Google Scholar 

  37. E. Rockenstein, M. Mante, A. Adame, et al., “Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer’s disease,” Acta Neuropathol., 113, No. 3, 265–275 (2007).

    Article  PubMed  CAS  Google Scholar 

  38. A. Alvarez-Buylla, D. G. Herrera, and H. Wichterle, “The subventricular zone: source of neuronal precursors for brain repair,” Prog. Brain Res., 127, 1–11 (2000).

    Article  PubMed  CAS  Google Scholar 

  39. K. Jin, M. Minami, J. Q. Lan, et al., “Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat,” Proc. Natl. Acad. Sci. USA, 98, No. 8, 4710–4715 (2001).

    Article  PubMed  CAS  Google Scholar 

  40. A. Arvidsson, T. Collin, D. Kirik, et al., Nat. Med., 8, 963–970 (2002).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. V. N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia

    O. A. Gomazkov

  2. V. A. Almazov Federal Cardiac and Endocrinology Center, St. Petersburg, Russia

    V. V. Afanasiev

  3. N. I. Pirogov Russian National Medical Research University, Moscow, Russia

    S. A. Rumyantseva & V. A. Stupin

  4. First I. M. Sechenov Moscow State Medical University, Moscow, Russia

    E. V. Silina

  5. City Polyclinic No. 7, Nalchik, Russia

    O. A. Sokhova

Authors
  1. O. A. Gomazkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. V. Afanasiev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. A. Rumyantseva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. A. Stupin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. V. Silina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O. A. Sokhova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. A. Rumyantseva.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 111, No. 12, Iss. 2, Stroke, pp. 58–63, December, 2011.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gomazkov, O.A., Afanasiev, V.V., Rumyantseva, S.A. et al. Current Concepts of Neurocytoprotective Therapy. Neurosci Behav Physi 43, 374–379 (2013). https://doi.org/10.1007/s11055-013-9743-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-013-9743-y

Keywords

Search

Navigation